JP2008522981A5 - - Google Patents

Download PDF

Info

Publication number
JP2008522981A5
JP2008522981A5 JP2007544636A JP2007544636A JP2008522981A5 JP 2008522981 A5 JP2008522981 A5 JP 2008522981A5 JP 2007544636 A JP2007544636 A JP 2007544636A JP 2007544636 A JP2007544636 A JP 2007544636A JP 2008522981 A5 JP2008522981 A5 JP 2008522981A5
Authority
JP
Japan
Prior art keywords
alkyl
pharmaceutical composition
hydrogen
aryl
aralkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007544636A
Other languages
English (en)
Japanese (ja)
Other versions
JP4990155B2 (ja
JP2008522981A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/044451 external-priority patent/WO2006063154A1/en
Publication of JP2008522981A publication Critical patent/JP2008522981A/ja
Publication of JP2008522981A5 publication Critical patent/JP2008522981A5/ja
Application granted granted Critical
Publication of JP4990155B2 publication Critical patent/JP4990155B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2007544636A 2004-12-07 2005-12-07 プロテアソームを阻害するための組成物 Expired - Lifetime JP4990155B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US63436604P 2004-12-07 2004-12-07
US60/634,366 2004-12-07
US65593005P 2005-02-23 2005-02-23
US60/655,930 2005-02-23
PCT/US2005/044451 WO2006063154A1 (en) 2004-12-07 2005-12-07 Composition for proteasome inhibition

Publications (3)

Publication Number Publication Date
JP2008522981A JP2008522981A (ja) 2008-07-03
JP2008522981A5 true JP2008522981A5 (enExample) 2008-10-02
JP4990155B2 JP4990155B2 (ja) 2012-08-01

Family

ID=36143200

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007544636A Expired - Lifetime JP4990155B2 (ja) 2004-12-07 2005-12-07 プロテアソームを阻害するための組成物

Country Status (17)

Country Link
US (1) US7737112B2 (enExample)
EP (3) EP2261236B1 (enExample)
JP (1) JP4990155B2 (enExample)
KR (1) KR101299821B1 (enExample)
CN (2) CN102847136A (enExample)
AT (1) ATE499109T1 (enExample)
AU (1) AU2005313975B2 (enExample)
CA (1) CA2589921C (enExample)
CY (1) CY1111489T1 (enExample)
DE (1) DE602005026556D1 (enExample)
DK (1) DK1819353T3 (enExample)
ES (2) ES2549763T3 (enExample)
HU (1) HUE027850T2 (enExample)
IL (1) IL183607A (enExample)
PL (3) PL1819353T3 (enExample)
PT (3) PT2261236E (enExample)
WO (1) WO2006063154A1 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0509879A (pt) 2004-04-15 2007-10-16 Proteolix Inc compostos para inibição enzimática
US8198270B2 (en) * 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
US8088741B2 (en) * 2004-05-10 2012-01-03 Onyx Therapeutics, Inc. Compounds for enzyme inhibition
US9034846B2 (en) * 2004-10-10 2015-05-19 Universite De Liege Use of cyclodextrin for treatment and prevention of bronchial inflammatory diseases
NZ595196A (en) 2005-11-09 2013-03-28 Proteolix Inc Peptide-based compounds for enzyme inhibition
BRPI0713309A2 (pt) 2006-06-19 2012-04-17 Proteolix Inc compostos para inibição de enzimas
ES2684340T3 (es) * 2007-10-04 2018-10-02 Onyx Therapeutics, Inc. Inhibidores de proteasa epoxi cetona de péptidos cristalinos y síntesis de cetoepóxidos de aminoácidos
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
EA201170527A1 (ru) * 2008-10-01 2011-10-31 Др. Редди'С Лабораторис Лтд. Фармацевтические композиции, включающие соединения бороновой кислоты
EA035100B1 (ru) 2008-10-21 2020-04-28 Оникс Терапьютикс, Инк. Комбинированная терапия с применением пептид эпоксикетонов
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
EP2238973A1 (en) * 2009-04-07 2010-10-13 Cephalon France Lyophilized preparations of proteasome inhibitors
US11020363B2 (en) 2009-05-29 2021-06-01 Cydex Pharmaceuticals, Inc. Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
MX388477B (es) 2009-05-29 2025-03-12 Cydex Pharmaceuticals Inc Composiciones inyectables de melfalán que comprenden un derivado de ciclodextrina y métodos de fabricación y uso de las mismas.
US8853147B2 (en) * 2009-11-13 2014-10-07 Onyx Therapeutics, Inc. Use of peptide epoxyketones for metastasis suppression
BR112012022060A2 (pt) 2010-03-01 2018-05-08 Onyx Therapeutics Inc composto para a inibição de imunoproteassoma
RU2012147246A (ru) 2010-04-07 2014-05-20 Оникс Терапьютикс, Инк. Кристаллический пептидный эпоксикетонный ингебитор иммунопротеасомы
NZ773177A (en) 2012-01-23 2022-09-30 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
DK3702374T3 (da) 2012-02-15 2022-06-27 Cydex Pharmaceuticals Inc Fremsgangsmåde til fremstilling for cyclodextrin-derivater
KR20160033795A (ko) 2012-02-28 2016-03-28 사이덱스 파마슈티칼스, 인크. 알킬화된 시클로덱스트린 조성물 및 이의 제조 및 사용 방법
EP2827861A4 (en) * 2012-03-19 2016-03-16 Aposignal Bioscience Llc COMPOSITION AND METHODS FOR CELLULAR MODULATION
EP2662094B1 (en) * 2012-05-08 2024-04-17 Onyx Therapeutics, Inc. Cylodextrin Complexation Methods for Formulating Peptide Proteasome Inhibitors
JP2015516416A (ja) * 2012-05-08 2015-06-11 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドプロテアソーム阻害剤を調合するためのシクロデキストリン錯体形成法
US9309283B2 (en) 2012-07-09 2016-04-12 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
MX2015000813A (es) * 2012-07-18 2015-09-07 Onyx Therapeutics Inc Composiciones liposómicas de inhibidores de proteasoma basadas en epoxicetona.
WO2014018807A1 (en) * 2012-07-26 2014-01-30 Centrax International, Inc. Peptide epoxyketone compounds
CN109180780B (zh) * 2012-07-26 2022-03-18 圣特莱国际公司 多肽环氧酮化合物
AU2013302269A1 (en) * 2012-08-14 2015-03-12 Trillium Therapeutics Inc. Fluorinated epoxyketone-based compounds and uses thereof as proteasome inhibitors
US9636376B2 (en) * 2012-09-11 2017-05-02 Innopharma, Inc. Stable compositions of peptide epoxy ketones
WO2014066274A1 (en) 2012-10-22 2014-05-01 Cydex Pharmaceuticals, Inc. Alkylated cyclodextrin compositions and processes for preparing and using the same
MX2015006867A (es) * 2012-11-30 2015-10-05 Glaxosmithkline Llc Composicion farmaceutica novedosa.
US10076384B2 (en) 2013-03-08 2018-09-18 Symple Surgical, Inc. Balloon catheter apparatus with microwave emitter
IL241407B (en) 2013-03-13 2022-06-01 Univ California Compositions comprising anti-cd38 antibodies and carfilzomib
KR20150131276A (ko) 2013-03-14 2015-11-24 오닉스 세라퓨틱스, 인크. 디펩타이드 및 트리펩타이드 에폭시 케톤 프로테이스 억제제
AR095426A1 (es) 2013-03-14 2015-10-14 Onyx Therapeutics Inc Inhibidores tripeptídicos de la epoxicetona proteasa
MX372671B (es) 2013-07-19 2020-04-23 Onyx Therapeutics Inc Inhibidores de proteasoma de epoxicetona peptídica en combinacion con inhibidores de cinasa pim para el tratamiento de canceres.
JP6608442B2 (ja) * 2014-07-14 2019-11-20 セントラックス インターナショナル，インコーポレイテッド 酵素阻害に用いられるエポキシケトン化合物
US10851184B2 (en) 2014-08-22 2020-12-01 Cydex Pharmaceuticals, Inc. Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same
WO2016170489A1 (en) 2015-04-24 2016-10-27 Fresenius Kabi Oncology Ltd. Pharmaceutical compositions of proteasome inhibitor
TWI673049B (zh) * 2015-11-17 2019-10-01 臺北醫學大學 治療及／或預防纖維性疾病之胺基萘醌化合物
TWI759301B (zh) * 2016-05-24 2022-04-01 美商安美基公司 聚乙二醇化卡非佐米化合物
DK3494108T3 (da) 2016-08-05 2021-01-11 Amgen Inc Syntese af (s)-2-amino-4-methyl-1-((r)-2-methyloxiran-2-yl)-pentan-1-on og farmaceutisk acceptable salte deraf
WO2018038687A1 (en) 2016-08-22 2018-03-01 Mustafa Nevzat Ilaç Sanayii A.Ş. Pharmaceutical formulations comprising a bortezomib-cyclodextrin complex
US10098890B2 (en) 2016-10-29 2018-10-16 Cipla Limited Stable carfilzomib formulations
WO2018138556A1 (en) 2017-01-24 2018-08-02 Orbicular Pharmaceutical Technologies Pvt. Ltd. Non-aqueous carfilzomib compositions
CA3075714A1 (en) 2017-09-14 2019-03-21 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer
WO2019099715A1 (en) 2017-11-16 2019-05-23 Amgen Inc. Stable compositions of pegylated carfilzomib compounds
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
US20250302954A1 (en) 2022-05-11 2025-10-02 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023220641A2 (en) 2022-05-11 2023-11-16 Juno Therapeutics, Inc. Methods and uses related to t cell therapy and production of same
EP4611798A1 (en) 2022-11-02 2025-09-10 Celgene Corporation Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
WO2025035020A2 (en) 2023-08-09 2025-02-13 Amgen Inc. Methods of using carfilzomib
WO2025092827A1 (zh) * 2023-10-30 2025-05-08 上海汇伦医药股份有限公司 一种环氧类化合物及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5135919A (en) * 1988-01-19 1992-08-04 Children's Medical Center Corporation Method and a pharmaceutical composition for the inhibition of angiogenesis
US5441944A (en) * 1989-04-23 1995-08-15 The Trustees Of The University Of Pennsylvania Substituted cyclodextrin sulfates and their uses as growth modulating agents
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5340736A (en) 1991-05-13 1994-08-23 The President & Fellows Of Harvard College ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting
AU4499697A (en) 1996-09-13 1998-04-02 New York University Method for treating parasitic diseases with proteasome inhibitors
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6133248A (en) * 1997-06-13 2000-10-17 Cydex, Inc. Polar drug of prodrug compositions with extended shelf-life storage and a method of making thereof
US6831099B1 (en) * 1999-05-12 2004-12-14 Yale University Enzyme inhibition
CA2385958A1 (en) 1999-10-20 2001-04-26 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone and hair growth
US7524883B2 (en) * 2002-01-08 2009-04-28 Eisai R&D Management Co., Ltd. Eponemycin and epoxomicin analogs and uses thereof
AU2003220685A1 (en) * 2002-04-09 2003-10-27 Greenville Hospital System Metastasis modulating activity of highly sulfated oligosaccharides
US7232818B2 (en) * 2004-04-15 2007-06-19 Proteolix, Inc. Compounds for enzyme inhibition
BRPI0509879A (pt) 2004-04-15 2007-10-16 Proteolix Inc compostos para inibição enzimática
US8088741B2 (en) * 2004-05-10 2012-01-03 Onyx Therapeutics, Inc. Compounds for enzyme inhibition

Similar Documents

Publication Publication Date Title
JP2008522981A5 (enExample)
JP2008509166A5 (enExample)
RU2397168C2 (ru) Производные тиофена в качестве ингибиторов снк 1
ES2396595T3 (es) Composición farmacéutica que contiene un derivado de pirazina y método de utilización de un derivado de pirazina en combinación
JOP20220069A1 (ar) عوامل محللة لـ brd9 ثنائية الوظيفة وطرق لاستخدامها
UY28132A1 (es) Derivados de pirrolopirimidina
NO20090328L (no) Nye forbindelser 385
TN2010000026A1 (fr) Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
JP2006509749A5 (enExample)
NO20072515L (no) 2-amido-4-fenyltnazolderivater, fremstilling og terapeutsik anvendelse derav
CY1114803T1 (el) Παραγωγα πυριμιδινο σουλφοναμιδιου ως ρυθμιστες υποδοχεων χημειοκινης
DK1689721T3 (da) Aminopyrazolderivater som GSK-3-ihibitorer
GB0914287D0 (en) Compositions
ATE386725T1 (de) Heterocyclylverbindungen
RU2002100058A (ru) Кристаллические производные 1-метилкарбапенема
AR054129A1 (es) Derivados de 2, 6-quinolinilo, una preparacion farmaceutica que los contiene y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades dependientes de integrinas alfa4beta1 y/o alfa4beta7
RU2008130887A (ru) Водорастворимое соединение бензоазепина и содержащая его фармацевтическая композиция
BR0311642A (pt) Formulação de divalproex de sódio de liberação aumentada
BRPI0609783A8 (pt) composto, utilização do mesmo, composição farmacêutica ou cosmética, e, utilização cosmética de um composto
JP2016536372A5 (enExample)
CL2020001156A1 (es) Formulaciones de liberación prolongada para aplicaciones intra-articulares.
BRPI0408270A (pt) composição farmacêutica compreendendo ácido 5-metil-2-(2'cloro-6'-fluoroanilino)fenilacético
FR2869615B1 (fr) Derives de l'acide butanoique, procedes pour leur preparation, compositions pharmaceutiques les contenant et leurs applications therapeutiques
JP4820648B2 (ja) ロテプレドノールエタボネート水性懸濁液剤
BRPI0519764A2 (pt) composiÇÕes farmacÊuticas derivadas de Ácido xanturÊnico e mÉtodos relacionados a estas